Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Kenneth Gordon

AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2019 Nov 20. PMID: 31748904.
      View in: PubMed
    2. Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A. Defining drug-free remission of skin disease in patients with plaque psoriasis. Br J Dermatol. 2019 Nov 09. PMID: 31705649.
      View in: PubMed
    3. Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2019 Oct 26. PMID: 31655974.
      View in: PubMed
    4. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2019 Oct 24. PMID: 31703821.
      View in: PubMed
    5. Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Oct 20. PMID: 31631377.
      View in: PubMed
    6. Serrano L, Maloney V, Gordon KB. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 Nov; 11(16):1357-1370. PMID: 31578912.
      View in: PubMed
    7. Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2019 Sep 03. PMID: 31479549.
      View in: PubMed
    8. Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep; 81(3):775-804. PMID: 31351884.
      View in: PubMed
    9. Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2019 Jul 22; 1-6. PMID: 31268369.
      View in: PubMed
    10. Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 Dec; 139(12):2437-2446.e1. PMID: 31207232.
      View in: PubMed
    11. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113. PMID: 30772097.
      View in: PubMed
    12. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072. PMID: 30772098.
      View in: PubMed
    13. Strober BE, Gordon KB. Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance. JAMA Dermatol. 2018 10 01; 154(10):1135. PMID: 29874363.
      View in: PubMed
    14. Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 10 04; 379(14):1313-1321. PMID: 30205746.
      View in: PubMed
    15. Ibler E, Gordon KB. IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018 Sep; 37(3):158-162. PMID: 30215632.
      View in: PubMed
    16. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661. PMID: 30097359.
      View in: PubMed
    17. Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Br J Dermatol. 2018 10; 179(4):984-986. PMID: 29747219.
      View in: PubMed
    18. Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304. PMID: 29524255.
      View in: PubMed
    19. Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949. PMID: 29706008.
      View in: PubMed
    20. Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683. PMID: 29799960.
      View in: PubMed
    21. Baldwin HE, Stein Gold LF, Gordon KB, Green JB, Leonardi CL, Sengelmann RD. Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar. Semin Cutan Med Surg. 2018 Jun; 37(4S):S75-S84. PMID: 30016379.
      View in: PubMed
    22. Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328. PMID: 29488226.
      View in: PubMed
    23. Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6. PMID: 29653208.
      View in: PubMed
    24. Gordon KB, Armstrong AW, Menter MA, Wu JJ. Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb; 37(2S):S44-S47. PMID: 29614137.
      View in: PubMed
    25. Armstrong AW, Gordon KB, Menter MA, Wu JJ. The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb; 37(2S):S39-S43. PMID: 29614136.
      View in: PubMed
    26. Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S48-S51. PMID: 29614138.
      View in: PubMed
    27. Wu JJ, Armstrong AW, Gordon KB, Menter MA. Practical Strategies for Optimizing Management of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S52-S55. PMID: 29614139.
      View in: PubMed
    28. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139. PMID: 28940259.
      View in: PubMed
    29. Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec; 77(6):1030-1037. PMID: 28993007.
      View in: PubMed
    30. Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179. PMID: 28964451.
      View in: PubMed
    31. Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K. Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™. Semin Cutan Med Surg. 2017 Jun; 36(4S):S52-S59. PMID: 28745729.
      View in: PubMed
    32. Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1004-1013. PMID: 28190255.
      View in: PubMed
    33. Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun; 76(6):1045-1053.e3. PMID: 28314685.
      View in: PubMed
    34. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431. PMID: 28057361.
      View in: PubMed
    35. Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 11 24; 375(21):2102. PMID: 27959738.
      View in: PubMed
    36. Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 02; 28(1):3-7. PMID: 27538247.
      View in: PubMed
    37. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug; 75(2):287-96. PMID: 27324314.
      View in: PubMed
    38. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56. PMID: 27299809.
      View in: PubMed
    39. Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9. PMID: 26953848.
      View in: PubMed
    40. Gordon KB. Translating the Science of Psoriasis. Semin Cutan Med Surg. 2016 Jun; 35(4 Suppl 4):S64. PMID: 27526392.
      View in: PubMed
    41. Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul; 75(1):33-41. PMID: 27210045.
      View in: PubMed
    42. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul; 75(1):77-82.e7. PMID: 27206759.
      View in: PubMed
    43. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct; 373(14):1318-28. PMID: 26422722.
      View in: PubMed
    44. Martin ML, Gordon K, Pinto L, Bushnell DM, Chau D, Viswanathan HN. The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015 Oct; 26(5):401-5. PMID: 25822169.
      View in: PubMed
    45. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44. PMID: 26154787.
      View in: PubMed
    46. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49. PMID: 26089047.
      View in: PubMed
    47. Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016 May; 30(5):864-5. PMID: 25773781.
      View in: PubMed
    48. Gordon KB. Update on New and Emerging Therapies in the Management of Psoriasis. Semin Cutan Med Surg. 2015 Mar; 34(2 Suppl):S34-6. PMID: 26623549.
      View in: PubMed
    49. Mercy KM, Gordon KB, Paller AS. Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA. 2014 Dec 24-31; 312(24):2676-7. PMID: 25536259.
      View in: PubMed
    50. Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76. PMID: 25284275.
      View in: PubMed
    51. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82. PMID: 25242558.
      View in: PubMed
    52. Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct; 24(5):523-32. PMID: 25115238.
      View in: PubMed
    53. Gordon KB, Strober BE. Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S20-3. PMID: 24979540.
      View in: PubMed
    54. Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S37-41. PMID: 24979544.
      View in: PubMed
    55. Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15. PMID: 24079852.
      View in: PubMed
    56. Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec; 169(6):1337-41. PMID: 24032554.
      View in: PubMed
    57. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep; 6(9 Suppl):S2-S20. PMID: 24167640.
      View in: PubMed
    58. Nwe SM, Champlain AH, Gordon KB. Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul; 9(7):677-82. PMID: 23899238.
      View in: PubMed
    59. Lingam P, Nwe S, Gordon KB. Systemics to topicals in psoriasis: the unfilled need. Br J Dermatol. 2013 Jul; 169(1):2-3. PMID: 23834112.
      View in: PubMed
    60. Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug; 24(4):255-60. PMID: 23249143.
      View in: PubMed
    61. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45. PMID: 23279003.
      View in: PubMed
    62. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct; 24(5):356-60. PMID: 23092173.
      View in: PubMed
    63. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61. PMID: 23157612.
      View in: PubMed
    64. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr; 72(4):517-24. PMID: 22562972.
      View in: PubMed
    65. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72. PMID: 22356258.
      View in: PubMed
    66. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec; 2(1):2. PMID: 23205325.
      View in: PubMed
    67. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2(1):1. PMID: 23205324.
      View in: PubMed
    68. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12. PMID: 22395580.
      View in: PubMed
    69. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14. PMID: 22011907.
      View in: PubMed
    70. Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012 Aug; 67(2):245-56. PMID: 22015149.
      View in: PubMed
    71. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51. PMID: 21978572.
      View in: PubMed
    72. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71. PMID: 21862748.
      View in: PubMed
    73. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51. PMID: 21752491.
      View in: PubMed
    74. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Maddox J, Weng HH, Wajdula J, Lin SL, Baumgartner SW. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011 Mar; 10(3):289-300. PMID: 21369647.
      View in: PubMed
    75. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74. PMID: 21306785.
      View in: PubMed
    76. Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb; 64(2):263-74. PMID: 21145618.
      View in: PubMed
    77. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010 Jul 27; 5:11-22. PMID: 20694136.
      View in: PubMed
    78. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56. PMID: 20605254.
      View in: PubMed
    79. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65. PMID: 20462664.
      View in: PubMed
    80. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010 Mar; 29(1):48-52. PMID: 20430307.
      View in: PubMed
    81. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010 Feb; 146(2):186-8. PMID: 20157030.
      View in: PubMed
    82. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan; 62(1):114-35. PMID: 19811850.
      View in: PubMed
    83. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009 Sep-Oct; 22(5):431-40. PMID: 19845720.
      View in: PubMed
    84. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46. PMID: 19527820.
      View in: PubMed
    85. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep; 61(3):451-85. PMID: 19493586.
      View in: PubMed
    86. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr; 60(4):643-59. PMID: 19217694.
      View in: PubMed
    87. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008 Dec 15; 102(12):1631-43. PMID: 19064017.
      View in: PubMed
    88. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371(9625):1665-74. PMID: 18486739.
      View in: PubMed
    89. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64. PMID: 18423261.
      View in: PubMed
    90. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50. PMID: 18423260.
      View in: PubMed
    91. Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15; 101(8):1119-26. PMID: 18394444.
      View in: PubMed
    92. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008 Apr; 4(2):345-51. PMID: 18728850.
      View in: PubMed
    93. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008 Jun; 58(6):1031-42. PMID: 18313171.
      View in: PubMed
    94. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb; 144(2):200-7. PMID: 18283176.
      View in: PubMed
    95. Gordon KB, Satoskar R. Therapeutics and immune-mediated skin disease. Curr Dir Autoimmun. 2008; 10:359-72. PMID: 18460896.
      View in: PubMed
    96. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol. 2007 Dec; 6(12):1205-12. PMID: 18189060.
      View in: PubMed
    97. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan; 58(1):94-105. PMID: 17980456.
      View in: PubMed
    98. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15. PMID: 17936411.
      View in: PubMed
    99. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101. PMID: 17689932.
      View in: PubMed
    100. Melhis SL, Gordon KB. The new psoriasis pathway: toward a unified theory of immunopathogenesis. Expert Rev Clin Immunol. 2007 Jul; 3(4):447-50. PMID: 20477148.
      View in: PubMed
    101. Horn E, Gordon K, Mease P. The first World Psoriasis and Psoriatic Arthritis Conference. J Invest Dermatol. 2007 Jul; 127(7):1566-7. PMID: 17568796.
      View in: PubMed
    102. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun; 143(6):719-26. PMID: 17576937.
      View in: PubMed
    103. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50. PMID: 18058494.
      View in: PubMed
    104. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007; 18(1):13-8. PMID: 17365261.
      View in: PubMed
    105. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr; 56(4):598-603. PMID: 17113190.
      View in: PubMed
    106. Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, Lingen MW. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep; 11(1):16-29. PMID: 17069007.
      View in: PubMed
    107. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606. PMID: 17010738.
      View in: PubMed
    108. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14. PMID: 16700803.
      View in: PubMed
    109. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr; 54(4 Suppl 1):S164-70. PMID: 16488338.
      View in: PubMed
    110. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91. PMID: 16488334.
      View in: PubMed
    111. Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S101-11. PMID: 16488320.
      View in: PubMed
    112. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006; 17(1):9-17. PMID: 16467018.
      View in: PubMed
    113. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec; 9(6):303-12. PMID: 16699904.
      View in: PubMed
    114. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53. PMID: 16225604.
      View in: PubMed
    115. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep; 27(9):1317-28. PMID: 16291408.
      View in: PubMed
    116. Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun; 141(6):683-7. PMID: 15967913.
      View in: PubMed
    117. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60. PMID: 15888152.
      View in: PubMed
    118. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33. PMID: 15761420.
      View in: PubMed
    119. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan; 141(1):82-4. PMID: 15655149.
      View in: PubMed
    120. Gordon KB. Patient education and advocacy groups: a means to better outcomes? Arch Dermatol. 2005 Jan; 141(1):80-1. PMID: 15655148.
      View in: PubMed
    121. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8. PMID: 15655139.
      View in: PubMed
    122. Gordon KB, Valentine J. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004 Dec; 8 Suppl 2:3-9. PMID: 15668749.
      View in: PubMed
    123. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):614-24. PMID: 15624744.
      View in: PubMed
    124. Mehlis S, Gordon KB. From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct; 22(4):371-7, vii-viii. PMID: 15450333.
      View in: PubMed
    125. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31. PMID: 15379777.
      View in: PubMed
    126. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80. PMID: 14679270.
      View in: PubMed
    127. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003 Dec; 2(6):624-8. PMID: 14711140.
      View in: PubMed
    128. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec; 139(12):1627-32; discussion 1632. PMID: 14676082.
      View in: PubMed
    129. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003 Dec; 139(12):1540-2. PMID: 14676068.
      View in: PubMed
    130. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003 Dec; 139(12):1563-70. PMID: 14676071.
      View in: PubMed
    131. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003 Nov; 49(5):816-25. PMID: 14576659.
      View in: PubMed
    132. Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct; 2(5):286-94. PMID: 14673261.
      View in: PubMed
    133. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S44-50. PMID: 12894125.
      View in: PubMed
    134. Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec; 28(12):1107-14; discussion 1114. PMID: 12472488.
      View in: PubMed
    135. Girvin AM, Gordon KB, Welsh CJ, Clipstone NA, Miller SD. Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood. 2002 May 15; 99(10):3692-701. PMID: 11986225.
      View in: PubMed
    136. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May; 138(5):657-63. PMID: 12020229.
      View in: PubMed
    137. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002; 25(13):913-27. PMID: 12381213.
      View in: PubMed
    138. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg. 2001 Dec; 20(4):242-9. PMID: 11770911.
      View in: PubMed
    139. Horn MA, Gordon KB. Chemoprevention of skin cancer. Cancer Treat Res. 2001; 106:255-82. PMID: 11225006.
      View in: PubMed
    140. Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg. 2000 Apr; 26(4):371-4. PMID: 10759827.
      View in: PubMed
    141. Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol. 1999 May; 112(5):775-81. PMID: 10233771.
      View in: PubMed
    142. Ward SK, Roenigk HH, Gordon KB. Dermatologic manifestations of gastrointestinal disorders. Gastroenterol Clin North Am. 1998 Sep; 27(3):615-36, vi. PMID: 9891700.
      View in: PubMed
    143. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol. 1998 May 01; 160(9):4271-9. PMID: 9574529.
      View in: PubMed
    144. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998 Feb; 110(2):103-9. PMID: 9457902.
      View in: PubMed
    145. Gordon KB, Roenigk HH, Gendleman M. Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Arch Dermatol. 1997 Jun; 133(6):691-3. PMID: 9197821.
      View in: PubMed
    146. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol. 1997 Mar; 136(3):415-20. PMID: 9115929.
      View in: PubMed
    147. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol. 1997 Jan 15; 158(2):614-21. PMID: 8992975.
      View in: PubMed
    148. Katz SK, Gordon KB, Roenigk HH. The cutaneous manifestations of gastrointestinal disease. Prim Care. 1996 Sep; 23(3):455-76. PMID: 8888338.
      View in: PubMed
    149. Gordon KB, Garden JM, Robinson JK. Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. Dermatol Surg. 1996 Aug; 22(8):723-8. PMID: 8780766.
      View in: PubMed
    150. Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, Roenigk H, Rosen S. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996 Feb; 34(2 Pt 1):304-6. PMID: 8642101.
      View in: PubMed
    151. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15; 75(8):2169-73. PMID: 7697608.
      View in: PubMed
    152. Gordon KB, Robinson J. Carbon dioxide laser vaporization for Bowen's disease of the finger. Arch Dermatol. 1994 Oct; 130(10):1250-2. PMID: 7944505.
      View in: PubMed
    153. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer. 1993 Aug 01; 72(3):843-9. PMID: 8334638.
      View in: PubMed
    Gordon's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _